Rigel Pharma (NASDAQ: RIGL) reported Q3 EPS of ($0.03), $0.04 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $28.1 million versus the consensus estimate of $27.2 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.